Welpar Pharmbizz IPO – Listing, Allotment, Subscription, GMP & DRHP
Last Updated Date: Nov 16, 2022Welpar Pharmbizz Limited, is engaged in the business of distributing pharmaceutical products of various healthcare companies such as Lupin, Intas Pharmaceuticals, Abbott Healthcare, Glaxo Smithkline Pharma, Torrent Pharmaceuticals, Macleods Pharmaceutical and many more.
Let’s have a detailed review of the company and analytics of the Welpar Pharmbizz IPO release date, IPO offer price, subscription, Welpar Pharmbizz IPO allotment, grey market price and other details like the company’s background, its financial positions, its promoters and other related things.
Welpar Pharmbizz IPO Review & Ratings
| IPO Ratings & Review | |
| Criteria | Ratings |
| Industry Sentiments | 8.5/10 |
| Industry Ranking | 7.8/10 |
| Company Background | 7.9/10 |
| Company Reputation | 7.9/10 |
| Competitive Edge | 7.7/10 |
| Financial Statements | 7.8/10 |
| Popularity Index | 8.4/10 |
| Promoters Reputation | 7.7/10 |
| Retail Appetite | 7.9/10 |
| Top Brokers Review | 7.9/10 |
| Overall Ratings | 8.1/10 |
| Star Ratings | ★★★★☆ |
Summary of Welpar Pharmbizz IPO
Welpar Pharmbizz Limited, is engaged in the business of distributing pharmaceutical products of various healthcare companies such as Lupin, Intas Pharmaceuticals, Abbott Healthcare, Glaxo Smithkline Pharma, Torrent Pharmaceuticals, Macleods Pharmaceutical and many more.The company’s key area of focus and business is around distribution of branded ethical medicines. Welpar Pharmbizz Limited works with more than 150 national and multi-national pharmaceutical companies, for distribution a product portfolio of more than 10,000 SKUs. Initial public offering of up to 50,50,000* Equity Shares of Rs. 10.00 each fully paid-up of the Company for cash at a price of Rs. [●] per Equity Share aggregating to Rs. [●] Lakh.
From FY 2015-16 to FY 2017-2018, as per the Restated Financial Statements,
- For the Period ended July 31, 2018 the total revenue of the Company as per the restated consolidated financials was Rs. 1,809.71 Lakh and Rs. 7,421.58 Lakh for the year ended March 31, 2018. Further, the PAT as per the restated consolidated financials for the period ended July 31, 2018 was Rs. 121.18 Lakh and fiscal year ended on March 31, 2018 was Rs. 390.29 Lakh.
- The net asset value per Equity Share was Rs. 1,312.30 and Rs. 1,264.70 as of May 30, 2018 and March 31, 2018, respectively, as per the Restated Standalone Financial Statements.
- Their profit after tax for the period May 10, 2018 to July 31, 2018 was Rs. 121.18 Lakh while that for the period April 01, 2018 to May 09, 2018 was Rs. 51.86 Lakh forming 6.70% and 6.83% of the total revenue respectively. profit after tax increased by 995.23% to Rs. 390.29 Lakh for the financial year 2017-18 from Rs. 35.64 Lakh for the financial year 2016-17 due to aforementioned reasons. profit after tax increased by 27.89% to Rs. 35.64 Lakh for the financial year 2016-17 from Rs. 27.86 Lakh for the financial year 2015-16.
The Promoters of this company are Mr. Paras Kanhaiyalal Chhajed, Mr. Dipesh Paras Chhajed, Mr. Manish Paras Chhajed. The lead manager to the issue is Gretex Corporate Services Private Limited and the Registrar to this issue is Link Intime India Private Limited.
Open Free* Demat A/C Now! Fill the details below
Welpar Pharmbizz IPO Date
The opening and the closing date of Welpar Pharmbizz IPO is not known yet.
Welpar Pharmbizz IPO Subscription
| Day / Date | QIB | NII | RII | Total Subscription |
| Day 1 | ||||
| Day 2 | ||||
| Day 3 | ||||
| Day 4 | ||||
| Day 5 | ||||
| Shares Offered or Net Issue |
The shares subscribed by the public will be updated herein on a daily basis, once the IPO is open for subscription.
Welpar Pharmbizz IPO Allotment Status
Here, you can find the Allotment Status of this IPO.
Welpar Pharmbizz IPO Price Band
The face value of each share is Rs 10, but the price band of the IPO is not yet disclosed.
Welpar Pharmbizz IPO Equity Share Offering
Initial public offering of up to [●] Equity Shares for cash at price of Rs. [●] per Equity Share (including a premium of Rs. [●] per Equity Share).
Welpar Pharmbizz Limited – Company Overview
Welpar Pharmbizz Limited (formerly known as Welcome Agencies) is the Public limited Company and Welcome Enterprises is a partnership Firm. Welcome Enterprises was incorporated as partnership Firm on August 09, 1982. Welpar Pharmbizz Limited holds the majority stake as partner in Welcome Enterprises.
Welpar Pharmbizz Limited, is engaged in the business of distributing pharmaceutical products of various healthcare companies such as Lupin, Intas Pharmaceuticals, Abbott Healthcare, Glaxo Smithkline Pharma, Torrent Pharmaceuticals, Macleods Pharmaceutical and many more. They operate as a C & F Agent, stockiest and distributor in Mumbai, Maharashtra based out of the office in Wadala, Mumbai and dispatch centre also in Mumbai.
Their product portfolio includes: a) Ethical Medicines b) Ayurveda Medicines c) Surgical Implants d) and Health Monitoring Systems from a large variety of suppliers which are leading pharmaceutical companies in the business.
Competitive Strengths of Welpar Pharmbizz Limited:
- Management and Employee expertise;
- Quality Service;
- Needs of customers;
- High level of customer satisfaction;
- Existing distribution and sales networks;
- Distribution network
Business strategies of Welpar Pharmbizz Limited:
- Using Established Relationships with Pharmaceutical Companies
- New Product Segments
- Enhancing & Retaining the Customer Base
- Improving Operational & Functional Efficiencies
- Building-up as a Professional Organisation
- Develop cordial relationship with the Suppliers, Customer and employees
- Believe in traditional marketing, which is the process of direct customer contact to create exchanges that satisfy the Company’s objectives.
Welpar Pharmbizz Limited – Financial Statements
A quick look into the past financial performance of the company to understand its performance of business and evaluate the growth prospectus:
Financial Summary:
| Amount (in INR & lakhs) | |||||
| 30-Jul-18 | 09-May-18 | 31-Mar-18 | 31-Mar-17 | 31-Mar-16 | |
| Total Assets | 5,061.25 | 4,389.67 | 4,039.94 | 2,139.21 | 2,063.55 |
| Total Revenue | 1,809.71 | 759.56 | 7,421.58 | 7,670.11 | 7,443.83 |
| Total Expense | 1,631.86 | 684.63 | 6,825.70 | 7,615.96 | 7,402.73 |
| Profit After Tax | 121.18 | 51.86 | 390.29 | 35.64 | 27.64 |
Earnings per Equity Share (in lakhs)
| 31-Jul-18 | 31-May-18 | 31-Mar-18 | 31-Mar-17 | 31-Mar-16 | |
| Basic & Diluted | 8.57 | 48.92 | 368.20 | 33.63 | 26.29 |
From the above statements, one could find that the Welpar Pharmbizz Limited may perform well.
Welpar Pharmbizz IPO – Promoters
The Promoters of this company are:
- Mr. Paras Kanhaiyalal Chhajed
- Mr. Dipesh Paras Chhajed
- Mr. Manish Paras Chhajed
List of Related Parties (Key Managerial Personnel)
- Mr. Dipesh Paras Chhajed – Promoter and Managing Director
- Mr. Kiran Paras Chhajed –Whole Time Director
- Mr. Manish Paras Chhajed – Promoter, Executive Director and Chief Financial Officer
- Ms. Mitti Mitesh Jain – Company Secretary and Compliance Officer
Interest in promotion of the Company
Company is currently promoted by the Promoters in order to carry on its present business. Promoters are interested in the Company to the extent of their shareholding and directorship of the Individual Promoter in the Company and the dividend declared, if any, by the Company. The Promoters are interested in the transactions entered into the Company and the Promoter Group.
Property Interest
The promoters along with the promoter group will continue to hold collectively some percentage of the equity share capital of the company. As a result of the same, they will be able to exercise significant influence over the control of the outcome of the matter that requires approval of the majority shareholders vote.
Interest in Intellectual Rights of the Company
Promoters has not shown any interest in acquiring the intellectual rights of the company.
Welpar Pharmbizz IPO Offer Details or Issue Details
| Particulars | No. Of Equity Shares |
| Equity Shares Offered | Up to 50,50,000* Equity Shares of Rs. 10.00 each fully paid-up of the Company for cash at a price of Rs. [●] per Equity Share aggregating to Rs. [●] Lakh |
| Of which: | |
| Reserved for Market Makers | [●] Equity Shares of Rs. 10.00 each fully paid-up of the Company for cash at a price of Rs. [●] per Equity Share aggregating to Rs. [●] Lakh |
| Net Issue to the Public | [●] Equity Shares of Rs. 10.00 each fully paid-up of the Company for cash at a price of Rs. [●] per Equity Share aggregating to Rs. [●] Lakh |
| QIB Portion | [●] Equity Shares of Rs. 10.00 each fully paid-up of the Company are available for allocation |
| Of which | |
| Available for allocation to Mutual Funds only (5% of the QIB portion) (Excluding the Anchor Investor Portion) | [●] Equity Shares of Face Value of Rs. 10/- each |
| Balance for all QIBs including Mutual Funds | [●] Equity Shares of Face Value of Rs. 10/- each |
| Retail Investors Portion | [●] Equity Shares of Rs. 10.00 each fully paid-up of the Company for cash at a price of Rs. [●] per Equity Share aggregating to Rs. [●] Lakh will be available for allocation to Investors upto Rs. 2.00 Lakh |
| Non-Retail Investors Portion | [●] Equity Shares of Rs. 10.00 each fully paid-up of the Company for cash at a price of Rs. [●] per Equity Share aggregating to Rs. [●] Lakh will be available for allocation to Investors above Rs. 2.00 Lakh |
| Equity Shares outstanding prior to the Issue | 1,33,97,000 Equity Shares |
| Equity Shares outstanding after the Issue | Upto [●] Equity Shares of face value of Rs. 10 each |
Welpar Pharmbizz IPO Issue Object
These are the IPO Issue Objects of the company
- Funding the Working Capital requirements of the Company:
- Repayment/ pre-payment of certain unsecured loans availed from banks and financial institutions by the company; and
- General Corporate Purposes
Welpar Pharmbizz IPO – Basis of the Offer Price
The issue price is determined by the company in consultation with the Lead manager on the basis of the following qualitative and quantitative factors.
Qualitative factors are:
- Management and Employee expertise;
- Quality Service;
- Needs of customers;
- High level of customer satisfaction;
- Existing distribution and sales networks;
- Distribution network
The relevant quantitative factors are:
On the basis of standalone statement:-
| Basic & Diluted EPS | RONW in % | NAV (Rs.) | |
| 31-Mar-16 | 26.29 | 5.98 | – |
| 31-Mar-17 | 33.63 | 7.25 | – |
| 31-Mar-18 | 368.20 | 29.11 |
1264.70 |
- Competitive Peers:
They believe that there are no listed Companies in India which are engaged in the business of distributing pharmaceutical products of various healthcare companies.
Welpar Pharmbizz IPO Lead Managers
| Lead Managers |
| GRETEX CORPORATE SERVICES PRIVATE LIMITED Registered Office: Office no.102, 1st Floor, Kanakia Atrium-2, Chakala Andheri Kurla Road, Behind Courtyard Marriot, Mumbai – 400 093 Tel No.: +91 – 22 – 6708 6181 Email: info@gretexgroup.com Website: www.gretexcorporate.com Contact Person: Ms. Amina Khan SEBI Registration No: INM000012177 CIN: U74999MH2008PTC288128 |
Welpar Pharmbizz IPO Registrar to offer
| Registrar to the Offer |
| LINK INTIME INDIA PRIVATE LIMITED C-101, 1st Floor, 247, Park, L.B.S. Marg, Vikhroli (West), Mumbai – 400 083 Tel No.: +91 – 22 – 4918 6200 Fax No.: +91 – 22 – 4918 6195 Email: welpar.ipo@linkintime.co.in Website: www.linkintime.co.in Contact Person: Ms. Shanti Gopalkrishnan SEBI Registration No: INR000004058 CIN: U67190MH1999PTC118368 |
Other Details:
- Statutory Auditor – M/s Pankaj P. Sanghavi & Co., Chartered Accountants
- Peer Review Auditor – M/s Pankaj P. Sanghavi & Co., Chartered Accountants
- Bankers to the Company – NKGSB Co-op Bank Limited, Wadala
Welpar Pharmbizz IPO Review by Top 10 Stock Brokers
| Top Stock Brokers Review | Company Reputation | Competitive Edge | Financial Statement | Popularity Index | Promoters Reputation |
| Angel Broking | 7.5/10 | 7.4/10 | 8.5/10 | 8.1/10 | 7.1/10 |
| Sharekhan | 7.2/10 | 7.1/10 | 8.6/10 | 8.1/10 | 7.2/10 |
| Kotak Securities | 7.3/10 | 7.5/10 | 8.4/10 | 8.1/10 | 7.3/10 |
| ICICI Direct | 7.3/10 | 7.3/10 | 8.7/10 | 8.1/10 | 7.1/10 |
| IIFL | 7.5/10 | 7.2/10 | 8.8/10 | 8.0/10 | 7.1/10 |
| Edelweiss | 7.5/10 | 7.4/10 | 8.4/10 | 8.3/10 | 7.2/10 |
| Zerodha | 7.4/10 | 7.1/10 | 8.5/10 | 8.1/10 | 7.0/10 |
| 5Paisa | 7.1/10 | 7.1/10 | 8.4/10 | 8.1/10 | 7.1/10 |
| Karvy | 7.4/10 | 7.3/10 | 8.2/10 | 8.1/10 | 7.1/10 |
| Motilal Oswal | 7.1/10 | 7.1/10 | 8.6/10 | 8.3/10 | 7.2/10 |
Welpar Pharmbizz IPO Grey Market Premium
The Welpar Pharmbizz IPO Grey Market Premium price is Rs X, the Kostak rate is Rs X and the Subject to Sauda is X.
Open Free* Demat A/C Now! Fill the details below
Welpar Pharmbizz IPO News
News 1 – IPO ISSUE OPENS SOON (Download Prospectus)
Market Guide
Featured Topics